Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News > Health News
Audio By Carbonatix
8:30 AM on Friday, August 29
The Associated Press
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 29, 2025--
Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time.
A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com:https://www.businesswire.com/news/home/20250829028322/en/
CONTACT: Investors:
Shayla Gorman
(619) 393-1545Media:
Tracy Morris
(650) 380-4413
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY HEALTH TECHNOLOGY GENETICS SOFTWARE ARTIFICIAL INTELLIGENCE
SOURCE: Veracyte, Inc.
Copyright Business Wire 2025.
PUB: 08/29/2025 08:30 AM/DISC: 08/29/2025 08:30 AM
http://www.businesswire.com/news/home/20250829028322/en
